Bispecific antibody targeting IL-1R1 and NLPR3
US12227579B2 · kind B2 · utility
0Cited by
0References
12Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Sep 16, 2019 |
| Grant date | Feb 18, 2025 |
| Priority date | — |
| Expiry date | Mar 17, 2042 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/77
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure concerns modulators of the NLRP3 inflammasome pathway, in particular an NLRP3 inflammasome modulator which is capable of binding to both of IL-1R1 and NLRP3, for use in the treatment or prophylaxis of inflammatory eye diseases such as glaucoma.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.